Blood
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells
28
Nov
Nov
By Zaeem Shoaib
The U.S. Food and Drug Administration is investigating certain CAR T cancer therapies based on reports that they might cause a type of white blood cell to become cancerous in patients who received the treatment.
CAR T cell immunotherapies work by manipulating a patient’s own disease-fighting white blood cells called T cells…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Subscribe Now
Already a subscriber?
Log In
